Invention Grant
- Patent Title: Dihydroquinazolinones exhibiting protective activity against intracellular-acting toxins, intracellular viruses and bacteria
-
Application No.: US17296612Application Date: 2019-11-28
-
Publication No.: US12024508B2Publication Date: 2024-07-02
- Inventor: Jean-Christophe Cintrat , Julien Barbier , Daniel Gillet , Alain Pruvost , Audrey Couhert , Livia Tepshi , Robin Vinck
- Applicant: Commissariat a l'Energie Atomique et aux Energies Alternatives
- Applicant Address: FR Paris
- Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
- Current Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
- Current Assignee Address: FR Paris
- Agency: Morgan, Lewis & Bockius LLP
- Priority: FR 72016 2018.11.28
- International Application: PCT/EP2019/082976 2019.11.28
- International Announcement: WO2020/109510A 2020.06.04
- Date entered country: 2021-05-25
- Main IPC: C07D417/14
- IPC: C07D417/14 ; A61K47/59 ; A61K47/60

Abstract:
The invention relates to a new family of compounds of the type 2,3-dihydroquinazolin-4(1H)-one and the use thereof as inhibitors of the toxic effects of intracellular-acting toxins, such as ricin, Shiga toxins or the cholera toxin, using retrograde transport to intoxicate the cells, or viruses or bacteria using retrograde and/or syntaxin 5-dependent transport to infect the cells, specifically viruses or bacteria entering into the cells by means of endocytosis, or intracellular parasites.
Public/Granted literature
Information query